

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM570451

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Intellectual Property Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
GENEVANT SCIENCES LTD.		03/27/2020	Exempted Limited Company: BERMUDA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ROIVANT SCIENCES LTD.		
<b>Street Address:</b>	11-12 St. James's Square, Suite 1		
<b>City:</b>	London		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	SW1Y 4LB		
<b>Entity Type:</b>	Exempted Limited Company: BERMUDA		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86423056	GENVANCE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8004947512		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	202-370-4756		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Jay daSilva		
<b>Address Line 1:</b>	1025 Vermont Ave NW, Suite 1130		
<b>Address Line 2:</b>	COGENCY GLOBAL INC.		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>ATTORNEY DOCKET NUMBER:</b>	1206644 TM		
<b>NAME OF SUBMITTER:</b>	Theresa Volano		
<b>SIGNATURE:</b>	/Theresa Volano/		
<b>DATE SIGNED:</b>	04/03/2020		
<b>Total Attachments: 25</b>			
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page2.tif			
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page3.tif			
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page4.tif			

OP \$40.00 86423056

source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page5.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page6.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page7.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page8.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page9.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page10.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page11.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page12.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page13.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page14.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page15.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page16.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page17.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page18.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page19.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page20.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page21.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page22.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page23.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page24.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page25.tif  
source=Genevant - Intellectual Property Security Agreement - Trademark Filing#page26.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (“**Agreement**”) dated as of March 27, 2020, is made by GENEVANT SCIENCES LTD., an exempted limited company organized under the laws of Bermuda (the “**Company**”), and each of its direct or indirect subsidiaries signatory hereto (individually and collectively, the “**Grantor**”), in favor of ROIVANT SCIENCES LTD., an exempted limited company organized under the laws of Bermuda (together with its successors and assigns, “**Secured Party**”), in its capacity as Holder (as defined in the Note (as defined below)).

### RECITALS

A. The Company issued that certain Secured Promissory Note on the date hereof to Secured Party, which evidences an indebtedness of the Company to Secured Party (as amended or otherwise modified from time to time, the “**Note**”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Note.

B. Pursuant to the terms of the Note, the Company has agreed to cause Grantor to grant to Secured Party for its benefit a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Intellectual Property Collateral (as defined below).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Note, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Note, Grantor hereby grants and pledges to Secured Party for its benefit a security interest in all of Grantor’s right, title and interest in, to and under all of its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, owned, acquired or otherwise held (collectively, the “**Copyrights**”);

(b) Any and all inventions (whether or not patentable), know-how, trade secrets and any and all intellectual property rights in computer software, computer software products, databases and data collections, now or hereafter existing, created, owned, acquired or otherwise held;

(c) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues,

extensions, re-examination certificates, utility models, and continuations-in-part, now or hereafter existing, created, owned, acquired or otherwise held, including, without limitation, the patents and patent applications set forth on Exhibit A attached hereto (collectively, the “**Patents**”);

(d) Any trademarks, service marks, certification marks, trade names, trade dress, logos, domain names and social media identifiers, in each case, whether registered or not, applications to register and registrations any of the foregoing and like protections, now or hereafter existing, created, owned, acquired or otherwise held, including, without limitation, the items set forth on Exhibit B attached hereto, and the entire goodwill of the business of Grantor connected with or symbolized by any of the foregoing, (collectively, the “**Trademarks**”);

(e) All agreements now or hereafter in existence granting to Grantor, or pursuant to which any Grantor grants to any other person or entity, any license or other right to use or otherwise exploit any of the foregoing, and all fees, royalties and other payments or other consideration arising from or related to any of the foregoing, including, without limitation and to the extent in effect (which qualification also qualifies all representations and warranties with respect thereto made in the Note), those set forth on Exhibit C attached hereto;

(f) All amendments, renewals and extensions of any of the foregoing;

(g) All claims for, and rights to sue and collect damages, costs and expenses for, any and all past, present or future infringement, misappropriation or other violation of any of the foregoing; and

(h) All income, proceeds, royalties, payments, damages, costs and expenses now or hereafter due or payable with respect to any of the foregoing or any products related to any of the foregoing, including, without limitation, all payments under any insurance, indemnity or warranty payable in respect of any of the foregoing and all damages, costs and expenses for any and all past, present or future infringement, misappropriation or other violation of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include any “intent to use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall automatically constitute Intellectual Property Collateral.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks, the Register of Copyrights and any other U.S. or non-U.S. government officials to record and register this Agreement with the United States Patent and Trademark Office, United States Copyright Office and any other U.S. or non-U.S. government body (including, without limitation, the registration by Secured Party of this

Agreement with the Bermuda Registrar of Companies under Part V of the Companies Act 1981 of Bermuda), as applicable, upon request by Secured Party, including contemporaneously with the filing of any Intellectual Property Collateral with the United States Patent and Trademark Office, United States Copyright Office or such other U.S. or non-U.S. government body, as applicable. Grantor shall promptly provide to Secured Party copies of all applications that it files for any Intellectual Property Collateral, together with evidence of the recording of this Agreement as may be amended, restated, supplemented or otherwise modified from time to time, required for Secured Party to perfect and maintain a first priority perfected security interest in such property.

Grantor hereby authorizes Secured Party to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Further Assurances. Grantor shall take all such further actions and execute such further documents as Secured Party may reasonably request to confirm, record, register, perfect or validate the grant of security set forth in Section 1 of this Agreement or to otherwise enable Secured Party to protect and enforce such grant of security.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Note, which is hereby incorporated by reference. The provisions of the Note shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Secured Party with respect to the Intellectual Property Collateral are as provided by the Note, the Security Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

6. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign or otherwise transfer its obligations under this Agreement without Secured Party's express prior written consent, and any such attempted assignment in contravention of this Section 6 shall be void and of no effect. Secured Party may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Note without prior notice to Grantor, and all of such rights shall inure to the benefit of Secured Party's successors and assigns.

7. Governing Law. This Agreement shall be construed in accordance with, and this Agreement and all claims and causes of action arising out of the transactions contemplated hereby shall be governed by, the laws of the State of New York (other than choice of law rules that would require the application of the laws of any other jurisdiction).


The Grantor and Secured Party hereby waive the right to a trial by jury in any action under this Agreement or any action arising out of the transactions contemplated hereby, regardless of which party initiates such action.

[Signature pages follow]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

GENEVANT SCIENCES LTD.

By:   
\_\_\_\_\_  
Name: Marianne L. Romeo  
Title: Head, Global Transactions & Risk  
Management

GENEVANT SCIENCES GMBH

By:   
\_\_\_\_\_  
Name: Wenzel von der Heydte  
Title: Director

**SECURED PARTY:**

ROIVANT SCIENCES LTD.

By: 

\_\_\_\_\_  
Name: Marianne L. Romeo

Title: Head, Global Transactions & Risk  
Management



**EXHIBIT A****Patents**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Canada	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	2,742,955	05/13/2009		
GENEVANT SCIENCES GMBH	EPC	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	9825146.5	05/13/2009		
GENEVANT SCIENCES GMBH	Japan	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	2011-535577	05/13/2009		
GENEVANT SCIENCES GMBH	PCT	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	PCT/US2009/043852	05/13/2009		
GENEVANT SCIENCES GMBH	United States	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	13/127,968	05/13/2009	8,822,213	09/02/2014
GENEVANT SCIENCES GMBH	United States	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	14/173,730	02/05/2014	9,220,791	12/29/2015
GENEVANT SCIENCES GMBH	United States	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	14/957,429	12/02/2015		
GENEVANT SCIENCES GMBH	United States	BISPECIFIC INTRACELLULAR DELIVERY VEHICLES	61/171,381	04/21/2009		
GENEVANT SCIENCES GMBH	United States	BLOCK COPOLYMERS	14/908,351	07/30/2014	9,867,885	01/16/2018
GENEVANT SCIENCES GMBH	United States	BLOCK COPOLYMERS	15/827,793	11/30/2017		
GENEVANT SCIENCES GMBH	United States	BLOCK COPOLYMERS	61/860,136	07/30/2013		
GENEVANT SCIENCES GMBH	United States	BLOCK COPOLYMERS	61/868,122	08/21/2013		
GENEVANT SCIENCES GMBH	Australia	BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES	2014296278	07/30/2014		
GENEVANT SCIENCES GMBH	Australia	BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES	2020201384	02/26/2020		
GENEVANT SCIENCES GMBH	Canada	BLOCK COPOLYMERS AND THEIR CONJUGATES OR	2,919,828	07/30/2014		

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
		COMPLEXES WITH OLIGONUCLEOTIDES				
GENEVANT SCIENCES GMBH	EPC	BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES	14753175.0	07/30/2014		
GENEVANT SCIENCES GMBH	PCT	BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES	PCT/US2014/048839	07/30/2014		
GENEVANT SCIENCES GMBH	EPC	BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS	17885857.7	12/29/2017		
GENEVANT SCIENCES GMBH	PCT	BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS	PCT/US2017/068841	12/29/2017		
GENEVANT SCIENCES GMBH	United States	BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS	16/475,006	12/29/2017		
GENEVANT SCIENCES GMBH	United States	BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS	62/440,941	12/30/2016		
GENEVANT SCIENCES GMBH	United States	BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS	62/446,186	01/13/2017		
GENEVANT SCIENCES GMBH	Japan	DIBLOCK COPOLYMER AND POLYNUCLEOTIDE COMPLEX THEREOF FOR DELIVERY INTO CELL	2015-200236	10/08/2015	6239565	11/10/2017
GENEVANT SCIENCES GMBH	China P.R.	DIBLOCK COPOLYMER FOR INTRACELLULAR TRANSMISSION AND ITS POLYNUCLEOTIDE COMPOUND	200980122888.3	05/13/2009	ZL200980122888.3	07/10/2013
GENEVANT SCIENCES GMBH	China P.R.	DIBLOCK COPOLYMER FOR INTRACELLULAR TRANSMISSION AND ITS POLYNUCLEOTIDE COMPOUND	201310232498.X	05/13/2009	ZL201310232498.X	11/23/2016
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMER MICELLES AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	61/091,294	08/22/2008		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0162**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Australia	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2009246327	05/13/2009	2009246327	12/24/2013
GENEVANT SCIENCES GMBH	Australia	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2013204733	04/12/2013	2013204733	09/29/2016
GENEVANT SCIENCES GMBH	Brazil	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	PI0912159-5	05/13/2009		
GENEVANT SCIENCES GMBH	Canada	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2,724,105	05/13/2009	2,724,105	09/05/2017
GENEVANT SCIENCES GMBH	Canada	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2,972,694	05/13/2009		
GENEVANT SCIENCES GMBH	Canada	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	No. 3,065,577			
GENEVANT SCIENCES GMBH	EPC	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	France	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	Germany	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	India	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	8578/DELNP/2010	05/13/2009	294478	03/19/2018

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0163**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Ireland	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	Italy	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	502013902155060	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	Japan	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2011-509670	05/13/2009	5911723	04/08/2016
GENEVANT SCIENCES GMBH	Mexico	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	MX/a/2010/012238	05/13/2009	316902	01/07/2014
GENEVANT SCIENCES GMBH	PCT	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	PCT/US2009/043847	05/13/2009		
GENEVANT SCIENCES GMBH	Republic of Korea	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	10-2010-7027808	05/13/2009	10-1661636	09/26/2016
GENEVANT SCIENCES GMBH	Singapore	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	201008331-9	05/13/2009	166444	07/15/2013
GENEVANT SCIENCES GMBH	South Africa	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	2010/08729	05/13/2009	2010/08729	05/28/2014
GENEVANT SCIENCES GMBH	Spain	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	Switzerland	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0164**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	United Kingdom	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	09747510.7	05/13/2009	2281011	02/27/2013
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	12/992,517	05/13/2009	9,476,063	10/25/2016
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	15/264,392	09/13/2016	9,862,792	01/09/2018
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	15/828,078	11/30/2017		
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	61/052,908	05/13/2008		
GENEVANT SCIENCES GMBH	United States	DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS	61/171,377	04/21/2009		
GENEVANT SCIENCES GMBH	Israel	DIBLOCK COPOLYMERS AND USES THEREOF IN INHIBITING GENE EXPRESSION OR FOR INTRACELLULAR DELIVERY OF A POLYNUCLEOTIDE	209238	05/13/2009	209238	07/01/2014
GENEVANT SCIENCES GMBH	United States	ENDOSOMOLYTIC DIBLOCK COPOLYMER FOR SIRNA DELIVERY	61/052,914	05/13/2008		
GENEVANT SCIENCES GMBH	United States	FOLATE AND FOLATE ANALOG TARGETING MONOMERS AND POLYMERS HAVING FOLATE OR FOLATE ANALOG TARGETING BLOCKS	61/262,516	11/18/2009		
GENEVANT SCIENCES GMBH	Canada	HETEROGENEOUS POLYMERIC MICELLES FOR INTRACELLULAR DELIVERY	2,734,917	05/13/2009		
GENEVANT SCIENCES GMBH	EPC	HETEROGENEOUS POLYMERIC MICELLES	09808542.6	05/13/2009		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0165**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
		FOR INTRACELLULAR DELIVERY				
GENEVANT SCIENCES GMBH	Japan	HETEROGENEOUS POLYMERIC MICELLES FOR INTRACELLULAR DELIVERY	2011-523837	05/13/2009		
GENEVANT SCIENCES GMBH	PCT	HETEROGENEOUS POLYMERIC MICELLES FOR INTRACELLULAR DELIVERY	PCT/US2009/043859	05/13/2009		
GENEVANT SCIENCES GMBH	United States	HETEROGENEOUS POLYMERIC MICELLES FOR INTRACELLULAR DELIVERY	13/059,946	05/13/2009	9,211,250	12/15/2015
GENEVANT SCIENCES GMBH	Australia	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	2016209295	01/21/2016		
GENEVANT SCIENCES GMBH	Canada	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	2,974,503	01/21/2016		
GENEVANT SCIENCES GMBH	China P.R.	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	201680017499.4	01/21/2016		
GENEVANT SCIENCES GMBH	EPC	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	16703407.3	01/21/2016		
GENEVANT SCIENCES GMBH	Hong Kong	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	18108250.8	06/27/2018		
GENEVANT SCIENCES GMBH	India	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	201747028808	01/21/2016		
GENEVANT SCIENCES GMBH	Japan	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND	2017-539356	01/21/2016		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0166**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
		DIAGNOSTIC AGENTS INTO CELLS				
GENEVANT SCIENCES GMBH	PCT	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	PCT/US2016/014232	01/21/2016		
GENEVANT SCIENCES GMBH	United States	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	15/545,302	07/20/2017		
GENEVANT SCIENCES GMBH	United States	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	62/106,024	01/21/2015		
GENEVANT SCIENCES GMBH	United States	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	62/173,847	06/10/2015		
GENEVANT SCIENCES GMBH	United States	METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS	62/233,568	09/28/2015		
GENEVANT SCIENCES GMBH	Australia	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	2009246332	05/13/2009		
GENEVANT SCIENCES GMBH	Brazil	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	PI0911988-4	05/13/2009		
GENEVANT SCIENCES GMBH	Canada	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	2,724,472	05/13/2009		
GENEVANT SCIENCES GMBH	China P.R.	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	200980122892.X	05/13/2009		
GENEVANT SCIENCES GMBH	India	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	8550/DELNP/2010	05/13/2009		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0167**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Israel	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	209236	05/13/2009		
GENEVANT SCIENCES GMBH	Japan	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	2011-509673	05/13/2009		
GENEVANT SCIENCES GMBH	Mexico	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	MX/a/2010/012237	05/13/2009	296591.0	03/02/2012
GENEVANT SCIENCES GMBH	PCT	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	PCT/US2009/043853	05/13/2009		
GENEVANT SCIENCES GMBH	Republic of Korea	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	10-2010-7027811	05/13/2009		
GENEVANT SCIENCES GMBH	Singapore	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	201008327-7	05/13/2009		
GENEVANT SCIENCES GMBH	South Africa	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	2010/08732	05/13/2009	0.230187814933578	05/30/2012
GENEVANT SCIENCES GMBH	United States	MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS	12/992,541	05/13/2009		
GENEVANT SCIENCES GMBH	PCT	MICELLES OF HYDROPHILICALLY SHIELDED MEMBRANE-DESTABILIZING COPOLYMERS	PCT/US2009/043860	05/13/2009		
GENEVANT SCIENCES GMBH	United States	MICELLES OF HYDROPHILICALLY SHIELDED MEMBRANE-DESTABILIZING COPOLYMERS	13/127,962	05/13/2009		
GENEVANT SCIENCES GMBH	Australia	MICELLIC ASSEMBLIES	2009246329	05/13/2009	2009246329	02/20/2014
GENEVANT SCIENCES GMBH	Brazil	MICELLIC ASSEMBLIES	PI0911989-2	05/13/2009		
GENEVANT SCIENCES GMBH	Canada	MICELLIC ASSEMBLIES	2,724,014	05/13/2009	2,724,014	09/13/2016
GENEVANT SCIENCES GMBH	China P.R.	MICELLIC ASSEMBLIES	200980123440.3	05/13/2009		
GENEVANT SCIENCES GMBH	EPC	MICELLIC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	France	MICELLIC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0168**



GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Germany	MICELLC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	India	MICELLC ASSEMBLIES	8559/DELNP/2010	05/13/2009		
GENEVANT SCIENCES GMBH	Ireland	MICELLC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	Israel	MICELLC ASSEMBLIES	209239	05/13/2009		
GENEVANT SCIENCES GMBH	Italy	MICELLC ASSEMBLIES	502013902155061	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	Japan	MICELLC ASSEMBLIES	2011-509671	05/13/2009	5755563	06/05/2015
GENEVANT SCIENCES GMBH	Japan	MICELLC ASSEMBLIES	2015-107802	05/27/2015		
GENEVANT SCIENCES GMBH	Mexico	MICELLC ASSEMBLIES	MX/a/2010/012239	05/13/2009	315375	11/15/2013
GENEVANT SCIENCES GMBH	PCT	MICELLC ASSEMBLIES	PCT/US2009/043849	05/13/2009		
GENEVANT SCIENCES GMBH	Republic of Korea	MICELLC ASSEMBLIES	10-2010-7027809	05/13/2009	10-1764427	08/02/2017
GENEVANT SCIENCES GMBH	Singapore	MICELLC ASSEMBLIES	201008332-7	05/13/2009		
GENEVANT SCIENCES GMBH	South Africa	MICELLC ASSEMBLIES	2010/08730	05/13/2009	2010/08730	05/30/2012
GENEVANT SCIENCES GMBH	Spain	MICELLC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	Switzerland	MICELLC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	United Kingdom	MICELLC ASSEMBLIES	09747512.3	05/13/2009	2285853	02/27/2013
GENEVANT SCIENCES GMBH	United States	MICELLC ASSEMBLIES	12/992,525	05/13/2009	9,339,558	05/17/2016
GENEVANT SCIENCES GMBH	United States	MICELLC ASSEMBLIES	15/059,026	03/02/2016	9,662,403	05/30/2017
GENEVANT SCIENCES GMBH	United States	MICELLC ASSEMBLIES	15/499,683	04/27/2017	10,420,790	09/24/2019
GENEVANT SCIENCES GMBH	United States	MICELLC ASSEMBLIES	16/579,662	09/23/2019		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0169**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	United States	MICELLIC ASSEMBLIES	61/112,048	11/06/2008		
GENEVANT SCIENCES GMBH	United States	MICELLIC ASSEMBLIES	61/140,774	12/24/2008		
GENEVANT SCIENCES GMBH	United States	MICELLIC ASSEMBLIES	61/171,369	04/21/2009		
GENEVANT SCIENCES GMBH	Canada	MULTIBLOCK COPOLYMERS	2,742,880	11/06/2009		
GENEVANT SCIENCES GMBH	China P.R.	MULTIBLOCK COPOLYMERS	200980148153.8	11/06/2009	102272179	03/12/2014
GENEVANT SCIENCES GMBH	EPC	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	France	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	Germany	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	India	MULTIBLOCK COPOLYMERS	3370/DELNP/2011	11/06/2009		
GENEVANT SCIENCES GMBH	Ireland	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	Israel	MULTIBLOCK COPOLYMERS	212459	11/06/2009		
GENEVANT SCIENCES GMBH	Italy	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	Japan	MULTIBLOCK COPOLYMERS	2011-534933	11/06/2009	5766611	06/26/2015
GENEVANT SCIENCES GMBH	Mexico	MULTIBLOCK COPOLYMERS	MX/a/2011/004242	11/06/2009	330456	05/29/2015
GENEVANT SCIENCES GMBH	PCT	MULTIBLOCK COPOLYMERS	PCT/US2009/063648	11/06/2009		
GENEVANT SCIENCES GMBH	Republic of Korea	MULTIBLOCK COPOLYMERS	10-2011-7012773	11/06/2009		
GENEVANT SCIENCES GMBH	Singapore	MULTIBLOCK COPOLYMERS	201103187-9	11/06/2009	171100	01/15/2014
GENEVANT SCIENCES GMBH	South Africa	MULTIBLOCK COPOLYMERS	2011/03289	11/06/2009	2011/03289	10/30/2013
GENEVANT SCIENCES GMBH	Spain	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0170**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Switzerland	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	United Kingdom	MULTIBLOCK COPOLYMERS	09825524.3	11/06/2009	2364330	03/25/2015
GENEVANT SCIENCES GMBH	United States	MULTIBLOCK COPOLYMERS	13/127,959	11/06/2009	9,464,300	10/11/2016
GENEVANT SCIENCES GMBH	United States	MULTIBLOCK COPOLYMERS	15/254,874	09/01/2016		
GENEVANT SCIENCES GMBH	United States	MULTIBLOCK COPOLYMERS	61/177,921	05/13/2009		
GENEVANT SCIENCES GMBH	United States	MULTIBLOCK COPOLYMERS	61/243,898	09/18/2009		
GENEVANT SCIENCES GMBH	United States	NUCLEIC ACID CONSTRUCTS AND METHODS OF USING THE SAME	16/543,324	08/16/2019		
GENEVANT SCIENCES GMBH	Canada	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	2,745,926	12/08/2009		
GENEVANT SCIENCES GMBH	EPC	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	09836724.6	12/08/2009		
GENEVANT SCIENCES GMBH	Japan	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	2011-540835	12/08/2009		
GENEVANT SCIENCES GMBH	PCT	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	PCT/US2009/067193	12/08/2009		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0171**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	United States	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	13/133,355	12/08/2009	9,593,169	03/14/2017
GENEVANT SCIENCES GMBH	United States	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	15/428,063	02/08/2017	10,066,043	09/04/2018
GENEVANT SCIENCES GMBH	United States	OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION	61/120,756	12/08/2008		
GENEVANT SCIENCES GMBH	United States	ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME	62/924,567	10/22/2019		
GENEVANT SCIENCES GMBH	Australia	POLYMERIC CARRIER	2009246321	05/13/2009		
GENEVANT SCIENCES GMBH	Canada	POLYMERIC CARRIER	2,724,455	05/13/2009		
GENEVANT SCIENCES GMBH	China P.R.	POLYMERIC CARRIER	200980123439.0	05/13/2009		
GENEVANT SCIENCES GMBH	EPC	POLYMERIC CARRIER	9747504	05/13/2009		
GENEVANT SCIENCES GMBH	Israel	POLYMERIC CARRIER	209237	05/13/2009		
GENEVANT SCIENCES GMBH	Japan	POLYMERIC CARRIER	2011-509666	05/13/2009		
GENEVANT SCIENCES GMBH	Mexico	POLYMERIC CARRIER	MX/a/2010/012236	05/13/2009		
GENEVANT SCIENCES GMBH	PCT	POLYMERIC CARRIER	PCT/US2009/043837	05/13/2009		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0172**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	Republic of Korea	POLYMERIC CARRIER	10-2010-7027810	05/13/2009		
GENEVANT SCIENCES GMBH	Singapore	POLYMERIC CARRIER	201008329-3	05/13/2009		
GENEVANT SCIENCES GMBH	South Africa	POLYMERIC CARRIER	2010/08731	05/13/2009		
GENEVANT SCIENCES GMBH	United States	POLYMERIC CARRIER	12/992,536	05/13/2009	9,006,193	04/14/2015
GENEVANT SCIENCES GMBH	United States	POLYMERIC CARRIER	14/630,477	02/24/2015		
GENEVANT SCIENCES GMBH	United States	POLYMERIC CARRIER	61/112,054	11/06/2008		
GENEVANT SCIENCES GMBH	United States	POLYMERIC CARRIER	61/140,779	12/24/2008		
GENEVANT SCIENCES GMBH	United States	POLYMERIC CARRIER	61/171,358	04/21/2009		
GENEVANT SCIENCES GMBH	PCT	TARGETED POLYMER BIOCONJUGATES	PCT/US2009/043839	05/13/2009		
GENEVANT SCIENCES GMBH	United States	TARGETED POLYMER BIOCONJUGATES	12/992,545	05/13/2009		
GENEVANT SCIENCES GMBH	United States	TARGETED POLYMER BIOCONJUGATES	61/120,769	12/08/2008		
GENEVANT SCIENCES GMBH	United States	TARGETED POLYMER BIOCONJUGATES	61/171,365	04/21/2009		
GENEVANT SCIENCES GMBH	PCT	TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS	PCT/US2010/056993	11/17/2010		
GENEVANT SCIENCES GMBH	United States	TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS	13/510,279	11/17/2010	9,415,113	08/16/2016
GENEVANT SCIENCES GMBH	United States	TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS	61/262,512	11/18/2009		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	THERAPEUTIC METHODS	62755196	NOV 2, 2018		
GENEVANT SCIENCES GMBH	PCT	THERAPEUTIC METHODS	PCTUS201905971 1	NOV 4, 2019		

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0173**

GRANTOR	COUNTRY	APPLICATION TITLE	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	GRANT DATE
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	LIPID NANOPARTICLES	62839452	APR 26, 2019		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	LIPID NANOPARTICLES	62867098	JUN 26, 2019		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	CONJUGATES AND METHODS FOR TREATING ACROMEGALY	62925659	OCT 24, 2019		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	CONJUGATES AND METHODS FOR TREATING LIVER FIBROSIS	62944963	DEC 6, 2019		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS	62975116	FEB 11, 2020		
GENEVANT SCIENCES GMBH	UNITED STATES OF AMERICA	CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS	62990939	MAR 17, 2020		

**EXHIBIT B****Trademarks**

<b>GRANTOR</b>	<b>COUNTRY</b>	<b>TRADEMARK</b>	<b>APPLICATION NUMBER</b>	<b>FILING DATE</b>	<b>REGISTRATION NUMBER</b>	<b>REGISTRATION DATE</b>
Genevant Sciences GmbH	Australia	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Canada	E-Helix Logo	1,936,199	Dec-14-2018		
Genevant Sciences GmbH	China	E-Helix Logo	35345016	Dec-17-2018	35345016	Aug-7-2019
Genevant Sciences GmbH	China	E-Helix Logo	35345017	Dec-17-2018	35345017	Aug-7-2019
Genevant Sciences GmbH	China	E-Helix Logo	35345018	Dec-17-2018	35345018	Aug-7-2019
Genevant Sciences GmbH	EUTM	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	India	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	International Register	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Israel	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Japan	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	South Korea	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Mexico	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Russian Federation	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Singapore	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018
Genevant Sciences GmbH	Switzerland	E-Helix Logo	75361/2018	Jul-2-2018	725075	Dec-12-2018
Genevant Sciences GmbH	United Kingdom	E-Helix Logo	IR1455028	Dec-17-2018	IR1455028	Dec-17-2018

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0175**

GRANTOR	COUNTRY	TRADEMARK	APPLICATION NUMBER	FILING DATE	REGISTRATION NUMBER	REGISTRATION DATE
Genevant Sciences GmbH	United States of America	E-Helix Logo	79/254,078	Dec-17-2018		
Genevant Sciences GmbH	Argentina	GENEVANT	3.703.496	Apr-24-2018	3.021.246	Sep-24-2019
Genevant Sciences GmbH	Argentina	GENEVANT	3.703.497	Apr-24-2018	3.021.247	Sep-24-2019
Genevant Sciences GmbH	Argentina	GENEVANT	3.703.498	Apr-24-2018		
Genevant Sciences GmbH	Australia	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Bermuda	GENEVANT	57403	Dec-3-2018		
Genevant Sciences GmbH	Brazil	GENEVANT	914570420	Apr-24-2018	914570420	Apr-16-2019
Genevant Sciences GmbH	Brazil	GENEVANT	914570510	Apr-24-2018	914570510	Apr-16-2019
Genevant Sciences GmbH	Brazil	GENEVANT	914570609	Apr-24-2018	914570609	Apr-16-2019
Genevant Sciences GmbH	Canada	GENEVANT	1895171	Apr-23-2018		
Genevant Sciences GmbH	China	GENEVANT	30421155	Apr-23-2018	30421155	Mar-21-2019
Genevant Sciences GmbH	China	GENEVANT	30421156	Apr-23-2018	30421156	Mar-21-2019
Genevant Sciences GmbH	China	GENEVANT	30421157	Apr-23-2018	30421157	Mar-21-2019
Genevant Sciences GmbH	EUTM	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	India	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	International Register	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Israel	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0176**



GRANTOR	COUNTRY	TRADEMARK	APPLICATION NUMBER	FILING DATE	REGISTRATION NUMBER	REGISTRATION DATE
Genevant Sciences GmbH	Japan	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Korea (South)	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Mexico	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Norway	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Russian Federation	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Singapore	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Switzerland	GENEVANT	63382/2017	Oct-25-2017	711120	Dec-20-2017
Genevant Sciences GmbH	United Kingdom	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	United States of America	GENEVANT	79/237,909	Apr-23-2018		
Genevant Sciences GmbH	United States of America	GENEVANT	IR1415974	Apr-23-2018	IR1415974	Apr-23-2018
Genevant Sciences GmbH	Switzerland	Genevant Stylized (with E- Helix)	75392/2018	Jul-3-2018	724003	Nov-19-2018
Genevant Sciences GmbH	Australia	GENVANCE	1652789	Oct-16-2014	1652789	Jan-30-2015
Genevant Sciences GmbH	Brazil	GENVANCE	908456093	Oct-16-2014	908456093	Apr-4-2017
Genevant Sciences GmbH	EUTM	GENVANCE	012902367	May-23-2014	012902367	Oct-9-2014
Genevant Sciences GmbH	Japan	GENVANCE	2014087199	Oct-16-2014	5741141	Feb-13-2015
Genevant Sciences GmbH	Saudi Arabia	GENVANCE	1435022713	Oct-16-2014	1435022713	May-17-2016
Genevant Sciences GmbH	Switzerland	GENVANCE	621842014	Oct-16-2014	669852	Feb-23-2015

Error! Unknown document property name.

**TRADEMARK**  
**REEL: 006908 FRAME: 0177**

<b>GRANTOR</b>	<b>COUNTRY</b>	<b>TRADEMARK</b>	<b>APPLICATION NUMBER</b>	<b>FILING DATE</b>	<b>REGISTRATION NUMBER</b>	<b>REGISTRATION DATE</b>
Genevant Sciences GmbH	Turkey	GENVANCE	201483752	Oct-16-2014	201483752	Oct-16-2014
Genevant Sciences GmbH	United Kingdom	GENVANCE	3051849	Apr-16-2014	3051849	Apr-16-2014
Genevant Sciences GmbH	United States of America	GENVANCE	86/423,056	Oct-14-2014	4743640	May-26-2015

## **EXHIBIT C**

### **Agreements**

- Cross-License Agreement by and between Genevant Sciences GmbH (as assignee of Genevant Sciences Ltd.) and Arbutus Biopharma Corporation, dated as of April 11, 2018, as amended
- Amended and Restated RAFT Non-Exclusive License Agreement by and between the Commonwealth Scientific and Industrial Research Organisation and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of January 22, 2016
- Second Amended and Restated Exclusive Patent License Agreement between the University of Washington and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of February 9, 2016
- Amendment to Second Amended and Restated Exclusive Patent License Agreement between the University of Washington and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of September 22, 2017
- Side Letter between the University of Massachusetts and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of October 25, 2011
- Non-Exclusive License Agreement by and between Baylor College of Medicine and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of September 14, 2015
- Transgenic Mouse License between Mayo Foundation for Medical Education and Research, the Board of Regents of The University of Texas System, and Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.), dated as of November 28, 2016
- Agreement for the Development and cGMP Manufacture of a Liposomal Formulation between Genevant Sciences GmbH (as successor-in-interest to PhaseRx, Inc.) and Polymun Scientific Immunbiologische Forschung GmbH, dated as of March 18, 2017
- License and Co-Development Agreement by and between BioNTech RNA Pharmaceuticals GmbH and Genevant Sciences GmbH, dated as of July 4, 2018